Ensartinib in Resected ALK -Positive Non–Small-Cell Lung Cancer
New England Journal of Medicine · 09.07.2026 · 395 (2) · 151-161
DOI: 10.1056/nejmoa2518990 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 09.07.2026. Verfasst von Dongsheng Yue und 59 weiteren Autor:innen. Beteiligte Einrichtung: Department of Lung Cancer, Tianjin Medical University Institute and Hospital, Tianjin, China. Hauptthemen laut MEDLINE: Anaplastic Lymphoma Kinase, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: Betta Pharmaceuticals.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Lung Cancer, Tianjin Medical University Institute and Hospital, Tianjin, China.
- Division of Thoracic Tumor Multimodality Treatment and Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu.
- Department of Thoracic Surgery, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
- Department of Thoracic Surgery, Hunan Cancer Hospital, Changsha, China.
- Department of Thoracic Surgery, Second Hospital and Clinical Medical School, Lanzhou University, Lanzhou, China.
- Department of Thoracic Surgery, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
ORCID-Profile: Bin Li, Junfeng Liu
Förderung
- Betta Pharmaceuticals
Zitieren
APA
Yue, D., Huang, M., Song, P., Chen, Y., Li, B., Fu, J., Guo, J., Cheng, C., Chen, Q., Xu, S., Liu, H., Lv, F., Hu, J., Jiang, K., Mao, W., Shen, B., Ye, F., Li, J., Zhang, X., …, & Fu, T. (2026). Ensartinib in Resected ALK -Positive Non–Small-Cell Lung Cancer. New England Journal of Medicine, 395(2), 151-161. https://doi.org/10.1056/nejmoa2518990
Vancouver
Yue D, Huang M, Song P, Chen Y, Li B, Fu J, et al. Ensartinib in Resected ALK -Positive Non–Small-Cell Lung Cancer. New England Journal of Medicine. 2026;395(2):151-161. doi:10.1056/nejmoa2518990
BibTeX
@article{Yue2026,
author = {Yue, Dongsheng and Huang, Meijuan and Song, Pingping and Chen, Yuejun and Li, Bin and Fu, Junke and Guo, Jianji and Cheng, Chao and Chen, Qixun and Xu, Shidong and Liu, Hongxu and Lv, Fang and Hu, Jian and Jiang, Ke and Mao, Weimin and Shen, Bo and Ye, Feng and Li, Jie and Zhang, Xueying and Guo, Shiping and Yu, Bentong and Zhu, Yuming and Wu, Ming and Zheng, Wei and Chen, Fang and He, Zhengfu and Bai, Yuansong and Xin, Hua and Chen, Keneng and Mao, Naiquan and Zhang, Yu and Wang, Bo and Zhang, Lei and Chen, Xingwu and Mei, Xinyu and Miao, Liyun and Wang, Runjie and Li, Gaofeng and Yao, Juntao and Zhao, Jun and Chen, Chun and Liu, Junfeng and Wei, Li and Yan, Xiaolong and Jin, Bo and Liu, Xianling and Liu, Zhidong and Tian, Hui and Xing, Wenqun and Yang, Lin and Ge, Di and Li, Xiangnan and Li, Shanqing and Song, Yongxiang and Zang, Aimin and Zhang, Dahai and Zhuang, Wu and Liu, Zijin and Yuan, Xiaobin and Fu, Tao},
title = {Ensartinib in Resected ALK -Positive Non–Small-Cell Lung Cancer},
journal = {New England Journal of Medicine},
year = {2026},
volume = {395},
number = {2},
pages = {151--161},
doi = {10.1056/nejmoa2518990}
}
EUVIMED